Abstract
The increased development and availability of therapeutic proteins (TP) requires a greater understanding of drug-drug interactions (DDI) in a poly-pharmacy environment. Medications that are likely co-administered in various patient populations have to be considered in the context of direct pharmacokinetic properties of co-administered drugs as well as indirect effects due to disease modification. Anticipating and managing drug-drug interactions are an important part of the clinical development of both small and large molecules. Animal models may provide useful information in this regard with respect to human translatability. However, very limited work has been done to better understand the value of animal models for predicting the potential for TP DDI. Potential DDI mechanisms of TPs, with the exception of cytokine-mediated alteration of drug metabolizing enzymes and transporters, are less well known. This review discusses the potential value and specific challenges in the use of animal models for TP DDI evaluation.
Keywords: Animal, biotherapeutic, drug-drug interaction, Models, Interaction, pathophysiology, clinical DDI, Ab-receptor, drug metabolizing enzymes, metabolizing enzyme, translation.
Current Drug Metabolism
Title:Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics
Volume: 13 Issue: 7
Author(s): Eugenia Kraynov, Martin E. Dowty, Odette Odette A. Fahmi and Owen Fields
Affiliation:
Keywords: Animal, biotherapeutic, drug-drug interaction, Models, Interaction, pathophysiology, clinical DDI, Ab-receptor, drug metabolizing enzymes, metabolizing enzyme, translation.
Abstract: The increased development and availability of therapeutic proteins (TP) requires a greater understanding of drug-drug interactions (DDI) in a poly-pharmacy environment. Medications that are likely co-administered in various patient populations have to be considered in the context of direct pharmacokinetic properties of co-administered drugs as well as indirect effects due to disease modification. Anticipating and managing drug-drug interactions are an important part of the clinical development of both small and large molecules. Animal models may provide useful information in this regard with respect to human translatability. However, very limited work has been done to better understand the value of animal models for predicting the potential for TP DDI. Potential DDI mechanisms of TPs, with the exception of cytokine-mediated alteration of drug metabolizing enzymes and transporters, are less well known. This review discusses the potential value and specific challenges in the use of animal models for TP DDI evaluation.
Export Options
About this article
Cite this article as:
Kraynov Eugenia, E. Dowty Martin, Odette A. Fahmi Odette and Fields Owen, Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics, Current Drug Metabolism 2012; 13 (7) . https://dx.doi.org/10.2174/138920012802138705
DOI https://dx.doi.org/10.2174/138920012802138705 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Routine use of Corticosteroids to Prevent Inflammation Response in Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design New Strategies and Patent Therapeutics in EBV-Associated Diseases
Mini-Reviews in Medicinal Chemistry Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Mini-Reviews in Medicinal Chemistry PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Multicomponent Reactions Based on Fluoro-Containing Building Blocks
Current Organic Chemistry Models of Infection Before and After Stroke: Investigating New Targets
Infectious Disorders - Drug Targets Towards Drugs Targeting Multiple Proteins in a Systems Biology Approach
Current Topics in Medicinal Chemistry Sigma Receptor Activation Reduces Infarct Size at 24 Hours After Permanent Middle Cerebral Artery Occlusion in Rats
Current Neurovascular Research Chronic Granulomatous Disease in Childhood
Current Pediatric Reviews Work Related Asthma in the Textile Industry
Recent Patents on Inflammation & Allergy Drug Discovery Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets Local Inflammation in Chronic Upper Airway Disease
Current Pharmaceutical Design Developments in Synthesis of the Anti-inflammatory Drug, Celecoxib: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews High-Density Lipoprotein-Raising Strategies: Update 2010
Current Pharmaceutical Design Molecular Adjuvants Based on Plasmids Encoding Protein Aggregation Domains Affect Bone Marrow Niche Homeostasis
Current Gene Therapy TiO2-Nanowired Delivery of Mesenchymal Stem Cells Thwarts Diabetes- Induced Exacerbation of Brain Pathology in Heat Stroke: An Experimental Study in the Rat Using Morphological and Biochemical Approaches
CNS & Neurological Disorders - Drug Targets